Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Clopidogrel
Treatment for Ischemic heart disease
Typical Dosage: 75mg daily
Effectiveness
75%
Safety Score
70%
Clinical Trials
592
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
75mg daily
Time to Effect
2-7 days
Treatment Duration
6-12 months (post-ACS/PCI) or lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
60(Treat 60 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$80
Side Effect Mgmt:$30
Total Annual:$160
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$40,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$246
Comparison vs Aspirin
Cost Difference
+$80/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Clopidogrel Outcomes
for Ischemic heart disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Common Side Effects
Bleeding
+5%
Dyspepsia
+6%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
19 completed trials for Clopidogrel in Ischemic heart disease
Clopidogrel Only Before Percutaneous Coronary Intervention or Before Every Coronarography?
NCT00432120COMPLETEDPHASE3
INTERVENTIONAL
Prague, Czechia
Started: Mar 1, 2006
Effectiveness of Clopidogrel Resinate in PCI(PRIDE)
NCT01349777COMPLETEDPHASE4
1.06K participants
INTERVENTIONAL
Gangneung, South Korea +2 more
Started: Mar 15, 2010
Optimum Platelet Inhibition After Coronary Bypass Surgery
NCT00262275COMPLETEDNA
INTERVENTIONAL
Cambridge, United Kingdom
Started: Jul 1, 2002
Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
NCT01431495COMPLETEDPHASE4
219 participants
INTERVENTIONAL
Tunis, Tunisia
Started: Apr 1, 2010
Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting
NCT01584791COMPLETEDPHASE4
148 participants
INTERVENTIONAL
Seoul, South Korea
Started: Oct 1, 2010
Genotyping Influences Outcome of Coronary Artery Stenting
NCT02707445COMPLETEDNA
5K participants
INTERVENTIONAL
Started: Sep 1, 2011
Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents
NCT03056118COMPLETEDPHASE4
1.37K participants
INTERVENTIONAL
Started: May 2, 2011
Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.
NCT00724880COMPLETEDPHASE4
135 participants
INTERVENTIONAL
Started: Jun 1, 2006
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
NCT00140465COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Munich, Germany
Started: Oct 1, 2004
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan
NCT01069302COMPLETEDPHASE4
106 participants
INTERVENTIONAL
Kyoto, Japan
Started: Feb 1, 2010
Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
NCT03198741COMPLETEDPHASE4
783 participants
INTERVENTIONAL
Shenyang, China
Started: Jul 13, 2017
Comparison of Generic and Original Formulation of Clopidogrel
NCT01147133COMPLETEDPHASE4
75 participants
INTERVENTIONAL
Started: Nov 1, 2009
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
NCT00693069COMPLETEDPHASE3
120 participants
INTERVENTIONAL
Montreal, Canada
Started: Sep 1, 2004
Chronic Kidney Disease (CKD) Platelet Study
NCT03649711COMPLETEDPHASE3
76 participants
INTERVENTIONAL
Little Rock, United States +1 more
Started: Nov 1, 2018
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
NCT04418479COMPLETEDPHASE4
5.51K participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 10, 2020
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
NCT01094275COMPLETED
75 participants
OBSERVATIONAL
Houston, United States
Started: Jan 1, 2010
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
NCT01955200COMPLETEDPHASE4
1.72K participants
INTERVENTIONAL
Nanjing, China
Started: Oct 5, 2013
The Elderly ACS II Trial
NCT01777503COMPLETEDPHASE4
1.46K participants
INTERVENTIONAL
Reggio Emilia, Italy +1 more
Started: Nov 1, 2012
Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI
NCT02469740COMPLETEDPHASE4
61 participants
INTERVENTIONAL
Dooradoyle, Ireland
Started: Jul 1, 2015
Showing 20 of 605 total trials